| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Beta-adrenergic receptors (β1 and possibly β2).
|
|---|---|
| ln Vitro |
In vitro, Ecastolol exhibits beta-adrenergic receptor antagonism, reducing catecholamine-induced increases in heart rate and contractility. It may show cardioselectivity (β1 > β2). Quantitative in vitro activity data (e.g., IC50 or Ki values) is not detailed in publicly available sources.
|
| ln Vivo |
In vivo, Ecastolol has been studied for its cardiovascular effects, including reduction of heart rate, blood pressure, and myocardial oxygen consumption. It may have potential in treating hypertension, angina, and arrhythmias. Detailed dose-response and pharmacokinetic data are limited in publicly available literature.
|
| Enzyme Assay |
No specific cell-free beta-receptor binding assay protocol is detailed for Ecastolol. For beta-blockers, typical cell-free assays include radioligand binding studies using [3H]CGP-12177 or [125I]iodocyanopindolol and membrane preparations from tissues expressing β1 and β2 receptors.
|
| Cell Assay |
Beta-receptor antagonism is assessed in isolated tissue preparations (e.g., guinea-pig atria for β1, rat uterus for β2) or in cells expressing beta-receptors. Tissues are contracted with isoproterenol, and inhibition of the response by Ecastolol is measured. pA2 or IC50 values are calculated from concentration-response curves.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of cardiovascular disease (e.g., hypertensive rats, dogs with pacing-induced heart failure). Ecastolol is administered via oral gavage or intravenous injection. Endpoints include heart rate, blood pressure, cardiac output, and survival.
|
| ADME/Pharmacokinetics |
Molecular weight and formula are not readily available in public sources. Storage: typical for small-molecule drugs (desiccated, protected from light).
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a beta-blocker, potential toxicities include bradycardia, hypotension, bronchospasm (if non-selective), and fatigue. Standard toxicological studies would be required for drug development.
|
| Additional Infomation |
Ecastolol is a research-grade compound, not approved for therapeutic use in major markets. It has been studied as a potential cardiovascular agent. No FDA approval or recent clinical trials have been reported. Its mechanism involves beta-adrenergic receptor blockade.
|
| Molecular Formula |
C5H12O8S2
|
|---|---|
| Molecular Weight |
264.27398
|
| Exact Mass |
483.237
|
| CAS # |
77695-52-4
|
| PubChem CID |
208905
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.202g/cm3
|
| Boiling Point |
732.5ºC at 760 mmHg
|
| Flash Point |
396.8ºC
|
| Index of Refraction |
1.574
|
| LogP |
4.133
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
35
|
| Complexity |
612
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC(NC1=CC=C(OCC(O)CNCCC2=CC=C(OC)C(OC)=C2)C(C3=CC=NO3)=C1)=O
|
| InChi Key |
CGUIWXDBHIFQJV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H33N3O6/c1-4-5-26(31)29-19-7-9-22(21(15-19)23-11-13-28-35-23)34-17-20(30)16-27-12-10-18-6-8-24(32-2)25(14-18)33-3/h6-9,11,13-15,20,27,30H,4-5,10,12,16-17H2,1-3H3,(H,29,31)
|
| Chemical Name |
N-[4-[3-[2-(3,4-dimethoxyphenyl)ethylamino]-2-hydroxypropoxy]-3-(1,2-oxazol-5-yl)phenyl]butanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7840 mL | 18.9200 mL | 37.8401 mL | |
| 5 mM | 0.7568 mL | 3.7840 mL | 7.5680 mL | |
| 10 mM | 0.3784 mL | 1.8920 mL | 3.7840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
